18 Share Tips – 9th February 2026

Welcome to this week’s edition of 18 Share Tips – our weekly selection of top ASX shares, chosen by leading analysts, that we think are worth considering.

This week Jabin Hallihan of Family Financial Solutions, Tony Locantro of Alto Capital and Tony Paterno of Ord Minnett share their ‘Buy’, ‘Hold’ and ‘Sell’ recommendations.

Please note these share tips are simply recommendations and are in no way intended as financial advice. These share tips are general advice and don’t take into account any individual’s financial situation. Investors are advised to seek professional financial advice before investing.

Sign up to our mailing list and get our weekly batch of share tips sent straight to your inbox, every Monday.

Early Access to 18 Share Tips

Every Monday at 9AM, thousands of investors scramble to read the same tips at the same time. Prices move. Opportunities disappear. You’re always one step behind.

But with The Bull Premium you get access to 18 Share Tips on Friday morning, giving you 3 extra days to prepare.

So while others read Monday’s tips, you’re already positioned to win.

Jabin Hallihan, Family Financial Solutions

BUY RECOMMENDATIONS

BUY – CSL (CSL) 

CSL develops plasma therapies and vaccines for a global market. The company provides products to patients in more than 100 countries. The share price has fallen from $271.32 on August 18, 2025 to trade at $181.48 on February 5, 2026. Our fair value is $295 a share. Short term earnings noise obscures a high quality plasma franchise with structural demand growth. In a bull market, valuation normalisation and quality should deliver strong upside moving forward. 

BUY – Telstra Group (TLS) 

Telstra is Australia’s dominant telecommunications provider with infrastructure‑like cash flows. Reported net profit after tax of $2.3 billion in full year 2025 was up 31 per cent on the prior corresponding period. Cash earnings per share of 22.4 cents were up 12 per cent. The shares were trading at $4.935 on February 5, below our fair value of $5.40. Cost discipline, share buy-backs and resilient mobile earnings support steady upside in a market that still rewards defensiveness. On top of this, Telstra pays reliable, fully franked dividends. Its full year dividend of 19 cents a share in fiscal year 2025 was up 5.6 per cent on the prior corresponding period. TLS was recently trading on a dividend yield of 3.85 per cent.  

HOLD RECOMMENDATIONS

HOLD – Woolworths Group (WOW) 

The share price of this supermarket giant is slowly recovering after releasing its first quarter sales results in fiscal year 2026 to the market on October 29, 2025. While Woolworths acknowledged first quarter sales were below aspirations, group sales of $18.5 billion were up 2.7 per cent on the prior corresponding period.  Australian food sales were up 2.1 per cent. Competitive pricing and cost pressures limit near term upside, but scale advantages remain intact. The company’s defensive characteristics appeal in an economy of higher interest rates. 

HOLD – Auckland International Airport (AIA)

AIA controls New Zealand’s primary international gateway, giving it a competitive advantage. International passenger movements of 1.067 million in December 2025 were up 4 per cent compared to the prior corresponding period. Queenstown Airport, in which AIA has a stake, lifted international passenger numbers by 14 per cent in December 2025 when compared to the prior corresponding period. The shares were trading at $7.21 on February 5. Our fair value target is $8.45 a share. However, significant capital expenditure tempers near term returns. AIA has attractive long term assets, so it’s better to hold rather than chasing it in a bull market.

SELL RECOMMENDATIONS

SELL – National Australia Bank (NAB)

NAB is Australia’s largest business bank, benefiting from an oligopolistic market structure. Statutory net profit of $6.759 billion in full year 2025 was down 2.9 per cent on the prior corresponding period. A credit impairment charge of $833 million was up from $728 million in the previous year. In our view, the shares are materially overvalued and leave little margin for error. Capital is better redeployed into discounted quality.

SELL – Wesfarmers (WES)

This industrial conglomerate owns high quality businesses, such as Bunnings and Kmart Group. The company is diversified, with other businesses including Officeworks, Wesfarmers Chemicals, Energy and Fertilisers and industrial safety. Diversification is a benefit as it spreads risk. However, in our view, the stock remains significantly overvalued, with optimism already priced in. The stock was recently trading on a lofty price/earnings ratio above 32 times, so it’s exposed to a correction on signs of any weakness. We would be inclined to trim holdings and re-invest the proceeds in stocks offering better value.

Tony Locantro, Alto Capital

BUY RECOMMENDATIONS

BUY – Global X Ultra Short Nasdaq 100 Complex ETF (SNAS)

SNAS provides leveraged inverse exposure to the Nasdaq-100, typically rising by about 2 per cent to 2.75 per cent for every 1 per cent fall in the index on a daily basis. With US technology valuations recently elevated and market leadership increasingly narrow, this ETF offers a tactical hedge against short term weakness in growth equities. SNAS is designed for short term positioning and can be impacted by compounding effects if held for extended periods. However, during periods of heightened volatility or sharp market corrections, downside moves in the Nasdaq can translate into meaningful gains.

BUY – Legacy Minerals Holdings (LGM)

This exploration company focuses on gold, silver and base metals targets in New South Wales, with its flagship Mt Carrington project located in the Lachlan Fold Belt. Recent funding has strengthened the balance sheet and supports ongoing drilling across priority targets. The company is also expected to release a revised scoping study for Mt Carrington in March, providing a key near term catalyst. While early stage exploration carries inherent geological risk, any success at Mt Carrington would be significant given LGM’s modest market capitalisation.

HOLD RECOMMENDATIONS

HOLD – Dimerix (DXB)

Dimerix is a clinical-stage biotechnology company advancing its lead asset DMX-200 in a global phase 3 trial for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder. Trial recruitment is complete, marking an important execution milestone, with regulatory engagement continuing. While progress remains encouraging, late stage clinical development is inherently binary, with key value inflection points still ahead. The current risk-reward profile supports a neutral stance as the program advances towards critical outcomes.

HOLD – Maronan Metals (MMA)

The company is advancing the polymetallic Maronan project in north-west Queensland, with exposure to silver, lead and copper in a proven mining region. The share price has strengthened on the back of rising silver prices and the release of a pre-economic study on the starter zone, which demonstrated strong financial metrics and supports the project’s development potential. Ongoing work programs provide meaningful news flow, with further upside possible following a recent re-rating.

SELL RECOMMENDATIONS

SELL – Northern Star Resources (NST)

Northern Star’s share price has performed strongly, supported by higher gold prices and improved sentiment towards large market capitalisation producers. However, the company’s most recent production report disappointed, with output and cost guidance undershooting market expectations. While the longer term outlook for gold remains positive, recent operational softness tempers near term confidence. With much of the upside already reflected in the share price, the risk-reward balance favours taking profits at current levels.

SELL – Mayfield Group Holdings (MYG)

This company provides electrical and telecommunication solutions across Australia’s power infrastructure. We previously recommended MYG as a buy in 18 Share Tips on August 28, 2023 when the shares were trading at 42 cents on August 24, 2023. The investment thesis has played out strongly, with the share price rising to above $3.50 and dividends paid along the way. MYG was trading at $2.57 on February 5, 2026. In January, 2026, the company upgraded profit guidance, flagging a materially stronger earnings outcome. While execution has been solid, the magnitude of the re-rating materially alters the risk-reward balance, making profit taking prudent.

Tony Paterno, Ord Minnett

BUY RECOMMENDATIONS

BUY – Zip Co (ZIP)

This digital financial company operates in Australia, New Zealand and the United States. There’s a lot to like about this buy now, pay later platform provider’s first quarter result in fiscal year 2026. Total transaction volume (TTV) growth in the US was up 47.2 per cent and revenue was up 51.2 per cent.  Consequently, Zip’s management has increased TTV guidance in the US to more than 40 per cent in full year 2026, which is up from 35 per cent. Margins were strong across the board, highlighted by an operating margin of 19.5 per cent in the first quarter, which is above the guidance range of between 16 per cent and 19 per cent for full year 2026. Margins are usually stronger in the second half.  

BUY – Praemium (PPS)

PPS provides an investment platform to enable financial advisers to manage client accounts. The company’s second quarter update in fiscal year 2026 revealed some encouraging trends, even if progress was uneven across its products. Improving inflows to the Powerwrap platform was a highlight, while Praemium SMA was impacted by a client transition. Overall, net inflows were solid and platform funds under administration of $32.5 billion were up 8 per cent and in line with expectations. We still see an improving outlook for PPS. 

HOLD RECOMMENDATIONS

HOLD – Bega Cheese (BGA)

Shares in this food and diary company have performed well since late 2025, with the price increasing from $5.15 on November 7 to trade at $6.21 on February 5, 2026. The company’s profitability has recovered as the gap between farmgate milk prices and global commodity prices has narrowed. However, farmgate milk price increases in fiscal year 2026 may limit further profit gains from the bulk segment. The company maintains its long term focus on achieving its fiscal year 2028 target of more than $250 million in earnings and a return on funds employed exceeding 10 per cent. 

HOLD – TechnologyOne (TNE)

TNE’s result in fiscal year 2025 disappointed the market with annual recurring revenue growth falling below consensus expectations. Offsetting the negative result was robust growth in the UK. TNE’s core segments continue to perform well. Early feedback on TNE’s recently launched artificial intelligence product Plus has been positive. TNE is one of the higher quality software businesses on the ASX and we remain positive about its outlook.   

SELL RECOMMENDATIONS

SELL – 4DMedical (4DX)

4DX is a respiratory imaging technology company. 4DX enjoyed a positive start to calendar year 2026 after the company announced UC San Diego Health had adopted its CT:VQ product. Also, the company completed a $150 million institutional placement to primarily accelerate the commercialisation of CT:VQ. The share price has risen from 32 cents on June 2, 2025 to trade at $3.16 on February 5, 2026. In our view, there’s a growing disconnect between 4DX’s valuation and the uncertainty around near term CT:VQ revenue generation. While we remain positive on 4DX’s technology, we pull back to a sell recommendation on valuation grounds. 

SELL – Iluka Resources (ILU)

The company reported solid production in the December quarter of 2025, but dire mineral sand prices has led the company to flag pre-tax impairments totalling $565 million in full year results. ILU’s mineral sands business clocked up net debt of $473 million at December 31, 2025. We suspect a capital raising may be an option to address the debt overhang as cash flow is impacted at operations at current prices. The shares were punished following the company update on January 29, 2026, falling from $6.96 on January 23 to trade at $5.17 on February 5.

The above recommendations are general advice and don’t take into account any individual’s objectives, financial situation or needs. Investors are advised to seek their own professional advice before investing. Please note that TheBull.com.au simply publishes broker recommendations on this page. The publication of these recommendations does not in any way constitute a recommendation on the part of TheBull.com.au. You should seek professional advice before making any investment decisions.